title: Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room
source: SeekingAlpha
date: 2025-10-16
url: https://finnhub.io/api/news?id=4da35621f2b556530db24678043e06ff991a116fc5bec80afc74bbffca16cbf4
Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming Q3 earnings release.
